Capsaicin 8% Topical System: An Advancement in the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet

Host: David M. Simpson, MD <br> Guest: Rory Abrams, MD <br> <p><strong>Find the full <span style="text-decoration: underline;"><a href="https://www.qutenza.com/pdfs/Qutenza_Prescribing_Information.pdf">Prescribing Information here</a></span>.</strong></p> <p>The STEP trial was the first-ever study assessing the efficacy and safety of the capsaicin 8% topical system for patients living with painful diabetic peripheral neuropathy (PDPN) of the feet. Here to share key findings from the trial and what this treatment might mean for our patients are Dr. David M. Simpson, principal investigator of the STEP trial, and Dr. Rory Abrams, an expert neurologist and author of a recent high-concentration capsaicin 8% topical system review paper. </p> <p>QUTENZA^® is a registered trademark of Averitas Pharma, Inc.<br /> © 2021 Averitas Pharma, Inc. All rights reserved.<br /> M-QZA-US-01-21-0048 June 2021</p>